Silence Therapeutics stock
SLNNASDAQSilence Therapeutics plc, HealthcareISIN US82686Q1013
44Score 44 out of 100, Weak
Price and trend
82 / 100
Price history
+194% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 104% above it.
Since April 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is at its 52-week high. Largest decline in 6 years: 92% (June 2021 to April 2025).
Chart figures for advanced users
- SMA 50$14.56
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.70
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.30
- The lowest closing price of the last twelve months.
- Resistance$19.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Silence Therapeutics plc belongs to the Biotechnology industry (United Kingdom) and, with a market value of $935.23M, is number 195 of 296 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2025 it reported revenue of $559K (down 98.7% year on year) and a loss of $88.61M.
Show more
- MEQIRI Score 44 out of 100 (Weak): rank 492 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $72.05M, financial debt $112K.Stability 69
Weaknesses
- Revenue shrinkingRevenue down 70.4% a year since 2020.Growth 32
- DilutionShare count up 47% since 2022.Capital allocation 18
- Volatile share priceVolatility 149% a year over the last 12 months.Stability 69
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Up to 2023 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue shrank 70.4% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 62%, operating −16056%, net −15852%. Last 12 months: net −100%. From 2020 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 17 Mar 2027in 125 days
- Last reported
- 12 Nov 2026below expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 22.3% since 15 Oct 2026.
- Earnings per share
- −0.37+22.3%
- Revenue
- $441.29K0.0%
- Earnings per share
- −0.55−0.1%
- Revenue
- $1.26M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $104.14M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Shares and prices per ordinary share as filed with the SEC, not per depositary receipt.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Silence Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 44
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Odyssey TherapeuticsODTX $1.01B44
- ImmaticsIMTX $1B29
- Climb BioCLYM $980.38M45
- PhilogenPHIL.MI $934.29M68
- Pharming GroupPHARM.AS $933.24M49
- ORIC PharmaceuticalsORIC $932.87M32
- MeiraGTx HoldingsMGTX $929.7M61
- Aktis OncologyAKTS $915.84M37
ETFs that hold Silence Therapeutics
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.06% | 0.35% | €1.21B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.